The estimated Net Worth of Johanna Friedl Naderer is at least $1.2 Million dollars as of 3 March 2023. Ms Naderer owns over 1,482 units of Vir Biotechnology Inc stock worth over $1,162,896 and over the last 3 years she sold VIR stock worth over $33,819.
Ms has made over 1 trades of the Vir Biotechnology Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she sold 1,482 units of VIR stock worth $33,819 on 3 March 2023.
The largest trade she's ever made was selling 1,482 units of Vir Biotechnology Inc stock on 3 March 2023 worth over $33,819. On average, Ms trades about 371 units every 0 days since 2022. As of 3 March 2023 she still owns at least 148,518 units of Vir Biotechnology Inc stock.
You can see the complete history of Ms Naderer stock trades at the bottom of the page.
Johanna Friedl-Naderer is the Exec. VP & COO at Vir Biotechnology Inc.
Ms Naderer is 53, she's been the Exec. VP & COO of Vir Biotechnology Inc since . There are 15 older and 8 younger executives at Vir Biotechnology Inc. The oldest executive at Vir Biotechnology Inc is Phillip Sharp, 75, who is the Independent Director.
Johanna's mailing address filed with the SEC is 1560 TRAPELO ROAD, , WALTHAM, MA, 02451.
Over the last 5 years, insiders at Vir Biotechnology Inc have traded over $197,171,926 worth of Vir Biotechnology Inc stock and bought 6,960,011 units worth $139,246,875 . The most active insiders traders include Norbert W Bischofberger, Endurance (Cayman) Ltd Sb I..., and Kristina Burow. On average, Vir Biotechnology Inc executives and independent directors trade stock every 7 days with the average trade being worth of $478,115. The most recent stock trade was executed by Janet Napolitano on 9 September 2024, trading 12,190 units of VIR stock currently worth $95,082.
vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
Vir Biotechnology Inc executives and other stock owners filed with the SEC include: